References
Key articles
National Poisons Information Service. TOXBASE: neuroleptic malignant syndrome. May 2023 [internet publication].Full text
Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Full text Abstract
Reference articles
1. Wargo KA, Gupta R. Neuroleptic malignant syndrome: no longer exclusively a "neuroleptic" phenomenon. J Pharm Technol. 2005;21:262-270.
2. Angelopoulos P, Markopoulou M, Kyamidis K, et al. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry. 2008 Sep-Oct;30(5):482-4. Abstract
3. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008 Sep;42(9):1290-7. Abstract
4. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008 Apr;28(4):530-5. Abstract
5. Velamoor VR, Fernando ML, Williamson P. Incipient neuroleptic malignant syndrome? Br J Psychiatry. 1990 Apr;156:581-4. Abstract
6. Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):265-9. Abstract
7. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994 Mar;182(3):168-73. Abstract
8. Gurrera RJ, Simpson JC, Tsuang MT. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry. 2007 Mar-Apr;48(2):205-11. Abstract
9. Chun TH, Mace SE, Katz ER, et al. Evaluation and management of children with acute mental health or behavioral problems. Part II: recognition of clinically challenging mental health related conditions presenting with medical or uncertain symptoms. Pediatrics. 2016 Aug 22;138(3):.Full text Abstract
10. Nielsen RE, Wallenstein Jensen SO, et al. Neuroleptic malignant syndrome - an 11-year longitudinal case-control study. Can J Psychiatry. 2012 Aug;57(8):512-8. Abstract
11. Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017 May;135(5):398-408. Abstract
12. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993 Jan;77(1):185-202. Abstract
13. Takubo H, Harada T, Hashimoto T, et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord. 2003;9(suppl 1):S31-S41. Abstract
14. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry. 1998 Aug;155(8):1113-6. Abstract
15. Levinson DF, Simpson GM. Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the 'neuroleptic malignant syndrome'. Arch Gen Psychiatry. 1986 Sep;43(9):839-48. Abstract
16. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986 Oct;143(10):1227-33. Abstract
17. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry. 1991 Jul;148(7):880-2. Abstract
18. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):415-22.Full text Abstract
19. Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination Database. J Clin Psychiatry. 2012 Apr;73(4):427-30. Abstract
20. Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021 Oct;144(4):329-41. Abstract
21. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981 Feb;31(2):132-7. Abstract
22. Hashimoto T, Tokuda T, Hanyu N, et al. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2003;9(suppl 1):S25-S30. Abstract
23. Mizuno Y, Takubo H, Mizuta E, et al. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinson Rel Disord. 2003;9(Suppl 1):S3-S9. Abstract
24. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007 Jun;164(6):870-6. Abstract
25. Heiman-Patterson TD. Neuroleptic malignant syndrome and malignant hyperthermia: important issues for the medical consultant. Med Clin North Am. 1993 Mar;77(2):477-92. Abstract
26. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry. 1997 Aug;154(8):1156-8. Abstract
27. Keck PE Jr, Pope HG Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989 Oct;46(10):914-8. Abstract
28. Gurrera RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol. 2002 Jul-Aug;25(4):183-93. Abstract
29. Abbar M, Carlander B, Castelnau D. Tricyclics and malignant syndrome. Eur Psychiatry. 1996;11(4):212-3. Abstract
30. Buckley P, Adityanjee M, Sajatovic M. Neuroleptic malignant syndrome. In: Katirji B, Kaminski HJ, Preston DC, et al, eds. Neuromuscular disorders in clinical practice. Boston, MA: Butterworth-Heinemann; 2002:1264-1275.
31. Lazarus A, Mann SC, Caroff SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press; 1989.
32. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet. 1991 Jul 20;338(8760):149-51. Abstract
33. Rosebush PI, Anglin RE, Richards C, et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol. 2008 Aug;28(4):459-61. Abstract
34. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999 Feb;156(2):169-80. Abstract
35. National Poisons Information Service. TOXBASE: neuroleptic malignant syndrome. May 2023 [internet publication].Full text
36. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Full text Abstract
37. Trollor JN, Chen X, Chitty K, et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012 Jul;201(1):52-6.Full text Abstract
38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
39. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996 Jan 1;39(1):1-4. Abstract
40. Mall GD, Hake L, Benjamin AB, et al. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. J Clin Psychopharmacol. 2008 Oct;28(5):572-3. Abstract
41. Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11:R4.Full text Abstract
42. National Institute for Health and Care Excellence. Parkinson’s disease in adults. July 2017 [internet publication].Full text
43. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000 Jul;85(1):129-35.Full text Abstract
44. Berardi D, Amore M, Keck PE Jr, et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998 Oct 15;44(8):748-54. Abstract
45. Groff K, Coffey BJ. Psychosis or atypical neuroleptic malignant syndrome in an adolescent? J Child Adolesc Psychopharmacol. 2008 Oct;18(5):529-32. Abstract
46. Oruch R, Pryme IF, Engelsen BA, et al. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017;13:161-75.Full text Abstract
47. Takanobu K, Okazaki D, Ogawa T, et al. Hyperosmolar hyperglycemic state secondary to neuroleptic malignant syndrome. Am J Emerg Med. 2015 Jan;33(1):126.e1-2. Abstract
48. Marshall PB, Mellman TA, Nguyen SX. Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine. Am J Psychiatry. 2008 Nov;165(11):1488-9. Abstract
49. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry. 2008 Jul;69(7):1157-65. Abstract
50. Viejo LF, Morales V, Punal P, et al. Risk factors in neuroleptic malignant syndrome: a case-control study. Acta Psychiatr Scand. 2003 Jan;107(1):45-9. Abstract
51. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717-25. Abstract
52. Ngo V, Guerrero A, Lanum D, et al. Emergent treatment of neuroleptic malignant syndrome induced by antipsychotic monotherapy using dantrolene. Clin Pract Cases Emerg Med. 2019 Feb;3(1):16-23.Full text Abstract
53. Bilanakis N, Peritogiannis V, Kalampokis G. Infections as complications of neuroleptic malignant syndrome. World J Biol Psychiatry. 2009;10(4 Pt 3):973-6. Abstract
54. Wadoo O, Ouanes S, Firdosi M. Neuroleptic malignant syndrome: a guide for psychiatrists. BJPsych Advances. 2020 Oct 23:1-10.
55. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012 May;24(2):155-62. Abstract
56. World Health Organization. International statistical classification of diseases and related health problems. 11th revision. January 2022 [internet publication].Full text
57. Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13(3):395-406. Abstract
58. Royal College of Anaesthetists; College of Emergency Medicine. Safe sedation of adults in the emergency department. November 2012 [internet publication].Full text
59. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Br J Psychiatry. 1991 Nov;159:709-12. Abstract
60. Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, et al. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand. 2020 Sep;142(3):233-41.Full text Abstract
61. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999 Oct;33(5):650-9. Abstract
62. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005 Jun;21(2):125-7. Abstract
63. Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther. 1991;7(2):111-120. Abstract
64. Scheftner WA, Shulman RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther. 1992;8(4):267-279. Abstract
65. Rich CL, Cunningham LA, Maher CC, et al. The effect of modified ECT on serum creatine phophokinase. I. With intravenous atropine. Dis Nerv Syst. 1975 Dec;36(12):653-5. Abstract
66. Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009 Oct;67(9):272-83. Abstract
67. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998 Jul;19(1):73-82.Full text Abstract
68. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome: focus on treatment and rechallenge. Ann Pharmacother. 2016 Nov;50(11):973-81. Abstract
69. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol. 2005 Jul-Aug;28(4):197-204. Abstract
Comorbidities Manager reference articles
70. National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication]Full text
71. Horowitz M, Taylor DM. The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs. Chichester: Wiley-Blackwell; 2024.
72. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65(suppl 11):16-22 Abstract
73. Royal College of Physicians. National early warning score (NEWS2). Standardising the assessment of acute-illness severity in the NHS. December 2017 [internet publication]Full text
74. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 [internet publication]Full text
75. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text
76. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90Full text Abstract
77. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): systematic review and meta-analysis. Lancet. 2018 Apr 26;391(10131):1693-705 Abstract
78. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169. Abstract
79. National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. Clinical guideline CG174. May 2017 [internet publication]Full text
80. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72 Abstract
81. National Institute for Health and Care Excellence. Hypertension in adults. Nov 2023 [internet publication].Full text
82. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020 Sep 15;142(11):1028-39.Full text Abstract
83. NHS England. Toolkit for general practice in supporting older people living with frailty. March 2017 [internet publication]Full text
84. British Geriatrics Society (BGS), Getting It Right First Time (GIRFT). Six steps to better care for older people in acute hospitals. Jul 2023 [internet publication].Full text
85. Falk Erhag H, Guðnadóttir G, Alfredsson J, et al. The association between the clinical frailty scale and adverse health outcomes in older adults in acute clinical settings: a systematic review of the literature. Clin Interv Aging. 2023 Feb;18:249-61.Full text Abstract
86. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13 Abstract
87. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-S314.Full text Abstract
88. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text Abstract
89. British Medical Association, the Resuscitation Council (UK) and the Royal College of Nursing. Decisions relating to cardiopulmonary resuscitation. 2016 [internet publication].Full text
90. The National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]Full text
91. Office of the Public Guardian. Mental Capacity Act: making decisions. Jun 2023 [internet publication]Full text
92. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). January 2010 [internet publication]Full text
93. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Oct 2024 [internet publication].Full text
94. National Poisons Information Service. TOXBASE. Neuroleptic malignant syndrome. Dec 2020 [internet publication]Full text
95. Royal College of Emergency Medicine. Procedural sedation in the emergency department. August 2022 [internet publication].Full text
96. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017 Jul;101:17-22 Abstract
97. Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia. CMAJ. 2017 Apr 10;189(14):E517-8Full text Abstract
98. Wijeyakuhan N, Gruber R, Rattray NA. The cascade of benzodiazepine prescribing for hospitalized geriatric patients. J Community Hosp Intern Med Perspect. 2020 Oct 29;10(6):542-5Full text Abstract
99. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits: a reconsideration. J Psychopharmacol. 2013 Nov;27(11):967-71 Abstract
100. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021
101. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014 Aug;44(2):332-40Full text Abstract
102. Medicines and Healthcare products Regulatory Agency. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression. March 2020 [internet publication]Full text
103. Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication].Full text
104. Joint British Diabetes Societies for Inpatient Care. The management of the hyperosmolar hyperglycaemic state (HHS) in adults. Feb 2022 [internet publication].Full text
105. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 Abstract
106. Joint British Diabetes Societies for Inpatient Care. Self-management of diabetes in hospital. Feb 2023 [internet publication].Full text
107. Joint British Diabetes Societies for Inpatient Care. Glycaemic management during enteral feeding for people with diabetes in hospital. Apr 2024 [internet publication].Full text
108. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. Oct 2014 [internet publication].Full text
109. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].Full text
110. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. Dec 2022 [internet publication].Full text
111. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88Full text Abstract
112. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. March 2020 [internet publication]Full text
113. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38(9):1687-93 Abstract
114. Umapathysivam MM, Gunton J, Stranks SN, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024 Jan 1;47(1):140-3.Full text Abstract
115. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014 Dec;4(3-4):176-88Full text Abstract
116. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Nov 9;6(12):681-94 Abstract
117. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020 Oct;51(10):3156-68.Full text Abstract
118. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13 Abstract
119. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Full text Abstract
120. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Oct 13;44(6):1000-5Full text Abstract
121. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract
122. Emery A, Wells J, Klaus SP, et al. Underestimation of cognitive impairment in older inpatients by the Abbreviated Mental Test Score versus the Montreal Cognitive Assessment: cross-sectional observational study. Dement Geriatr Cogn Dis Extra. 2020 Sep-Dec;10(3):205-15.Full text Abstract
123. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium. Mar 2019 [internet publication].Full text
124. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Mar 2;43(4):496-502.Full text Abstract
125. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. Jan 2023 [internet publication].Full text
126. Tieges Z, Maclullich AMJ, Anand A, et al. Diagnostic accuracy of the 4AT for delirium detection in older adults: systematic review and meta-analysis. Age Ageing. 2021 May 5;50(3):733-43.Full text Abstract
127. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. 2023 [internet publication]Full text
128. Zhang XM, Jiao J, Xie XH, et al. The association between frailty and delirium among hospitalized patients: an updated meta-analysis. J Am Med Dir Assoc. 2021 Mar;22(3):527-34. Abstract
129. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Full text
130. Bishara D. Managing drugs with anticholinergic activity. Drug Ther Bull. 2023 Sep;61(9):135-9.Full text Abstract
131. Lisibach A, Gallucci G, Benelli V, et al. Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients: a cohort study comparing 19 anticholinergic burden scales. Br J Clin Pharmacol. 2022 Nov;88(11):4915-27.Full text Abstract
132. Smith H, Fligelstone H. Reducing patient and planetary harms from high anticholinergic burden medication. BMJ. 2024 Jan 15;384:e075708.Full text Abstract
133. Gracie TJ, Caufield-Noll C, Wang NY, et al. The association of preoperative frailty and postoperative delirium: a meta-analysis. Anesth Analg. 2021 Aug 1;133(2):314-23.Full text Abstract
134. Liu CY, Gong N, Liu W. The association between preoperative frailty and postoperative delirium: a systematic review and meta-analysis. J Perianesth Nurs. 2022 Feb;37(1):53-62.e1. Abstract
135. White S, Griffiths R, Baxter M, et al. Guidelines for the peri-operative care of people with dementia: guidelines from the Association of Anaesthetists. Anaesthesia. 2019 Jan 11;74(3):357-72Full text Abstract
136. Burton JK, Craig L, Yong SQ, et al. Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2021 Nov 26;(11):CD013307.Full text Abstract
137. Public Health England. Urinary tract infection: diagnostic tools for primary care. October 2020 [internet publication]Full text
138. Medicines and Healthcare products Regulatory Agency. Haloperidol (haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. Dec 2021 [internet publication]Full text
139. Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304.Full text Abstract
140. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.Full text Abstract
141. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;3:CD007726.Full text Abstract
142. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13 Abstract
143. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14. Abstract
144. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May 12;29(5):459-525Full text Abstract
145. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. Abstract
146. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 Abstract
147. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97Full text Abstract
148. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40Full text Abstract
149. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid. 2016 Jun;11(6)4-7Full text
150. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94 Abstract
151. Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17Full text Abstract
152. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S295-306.Full text Abstract
153. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].Full text
154. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Aug 2022 [internet publication].Full text
155. Joint British Diabetes Societies for Inpatient Care. Inpatient care of the frail older adult with diabetes. Feb 2023 [internet publication].Full text
156. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67Full text Abstract
157. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text Abstract
158. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010 Mar;137(3):544-51Full text Abstract
159. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8Full text
160. NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2019. Nov 2020 [internet publication]Full text
161. Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus. Jan 2023 [internet publication].Full text
162. TREND Diabetes. End of life guidance for diabetes care. November 2021 [internet publication]Full text
163. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication]Full text
164. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 May 18;34(7):1517-8Full text Abstract
165. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21Full text Abstract
166. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51Full text Abstract
167. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2024 [internet publication].Full text
168. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897Full text Abstract
169. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2019 [internet publication]Full text
170. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Jan 2023 [internet publication].Full text
171. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308Full text Abstract
172. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77.Full text Abstract
173. Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax. 2024 Mar 26;79(suppl 1):3-11.Full text Abstract
174. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023 Sep 12;9(9):CD015226.Full text Abstract
175. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.Full text Abstract
176. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 June 28;6(6):CD006103Full text
Use of this content is subject to our disclaimer